Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK5757 for Cognitive Impairment in Schizophrenia
NCT00848484Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing MK5757 with Placebo (2 arms). Primary endpoint: Brief Assessment of Cognition in Schizophrenia Composite Score at Week 2. Started Oct 2008; status: completed.
02
Drugs
MK-5757
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00848484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848484.